{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Severity of treatment-emergent adverse events as assessed by the NCI CTCAE Version 5.0. This outcome measure applies only to participants in the dose expansion cohorts.","groups":[{"description":"SBT6050 plus trastuzumab deruxtecan\n\nSBT6050: Dosed with 0.45 mg/kg by subcutaneous (SC) injection in 21-day cycles\n\ntrastuzumab deruxtecan: 6.4 mg/kg by IV infusion in 21-day cycles","id":"OG000","title":"SBT6050 + T-DXd (6.4 mg/kg)"},{"description":"SBT6050 plus tucatinib and trastuzumab\n\nSBT6050: Dosed with 0.45 mg/kg by subcutaneous (SC) injection in 21-day cycles\n\ntucatinib: 300 mg by mouth (PO) twice daily (BID)\n\ntrastuzumab: 8 mg/kg loading dose (first dose), then 6 mg/kg maintenance dose (subsequent doses) IV infusion in 21-day cycles","id":"OG001","title":"SBT6050 + Tucatinib + Trastuzumab"}],"populationDescription":"No participants were enrolled in the dose expansion cohorts; study was terminated by Sponsor.","reportingStatus":"POSTED","timeFrame":"0 weeks","title":"Number of Participants With Treatment-emergent Adverse Events","type":"SECONDARY"}